STOCK TITAN

Longboard Pharmaceuticals, Inc. - $LBPH STOCK NEWS

Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: $LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longboard Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longboard Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.07%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
Longboard Pharmaceuticals, Inc.

Nasdaq:LBPH

LBPH Rankings

LBPH Stock Data

821.92M
25.54M
1.14%
63.94%
12.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LA JOLLA

About LBPH

longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.